EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy
- 26 October 2022
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1878 (1) , 188827
Abstract
No abstract availableKeywords
This publication has 151 references indexed in Scilit:
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinomaOral Oncology, 2013
- Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neckBritish Journal of Cancer, 2011
- Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I partBritish Journal of Cancer, 2011
- Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytesCancer Immunology, Immunotherapy, 2011
- Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and StressMolecular Cell, 2010
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalThe Lancet Oncology, 2010
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Structural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell, 2005